Interventions
Patients were randomly assigned, in a 1:1 ratio, to receive either any alkylating chemotherapy (temozolomide, lomustine, or the so-called PCV regimen that is a combination of procarbazine, lomustine, and vincristine) according to standard of care (SOC), or SOC together with disulfiram and nutritional copper supplement (SOC plus disulfiram and copper). Chemotherapy was given according to established treatment protocols. For patients randomized to SOC plus disulfiram and copper the administration of disulfiram and nutritional copper supplement started concomitant with the alkylating chemotherapeutic treatment. In the phase I study by Huang et al